Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies

References

• ParkinDMBrayFFerlayJPisaniPGlobal cancer statistics, 2002CA Cancer J Clin20055527410815761078
   PubMed Web of Science ®Google Scholar
• GarciaMJemalAWardEMHaoYSiegelRLThunMJGlobal Cancer Facts and Figures 2007Atlanta, GAAmerican Cancer Society2007
   Google Scholar
• CullinanSAMoertelCGWieandHSControlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancerJ Clin Oncol19941224124168113849
   PubMed Web of Science ®Google Scholar
• KimNKParkYSHeoDSA phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancerCancer19937112381338188508349
   PubMed Web of Science ®Google Scholar
• OhtsuAShimadaYShiraoKRandomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)J Clin Oncol2003211545912506170
   PubMed Web of Science ®Google Scholar
• WebbACunninghamDScarffeJHRandomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancerJ Clin Oncol19971512612678996151
   PubMed Web of Science ®Google Scholar
• Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study groupJ Clin Oncol200624314991499717075117
   PubMed Web of Science ®Google Scholar
• BlotWJDevesaSSKnellerRWFraumeniJFJrRising incidence of adenocarcinoma of the esophagus and gastric cardiaJAMA199126510128712891995976
   PubMed Web of Science ®Google Scholar
• ICH Expert Working GroupEthnic factors in the acceptability of foreign clinical data E5(R1)February 51998 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdfAccessed October 7, 2011
   Google Scholar
• BakerSDSparreboomAVerweijJClinical pharmacokinetics of docetaxel: recent developmentsClin Pharmacokinet200645323525216509758
   PubMed Web of Science ®Google Scholar
• HeidelbergerCChaudhuriNKDannebergPFluorinated pyrimidines, a new class of tumour inhibitory compoundsNature1957179456166366613418758
   PubMed Web of Science ®Google Scholar
• GremJL5-FluoropyrimidinesChabnerBALongoDLCancer Chemotherapy and Biotherapy2nd edPhiladelphia, PALippincott-Raven Publishers1996149211
   Google Scholar
• FraileRJBakerLHBurokerTRHorwitzJVaitkeviciusVKPharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusionCancer Res1980407222322287388790
   PubMed Web of Science ®Google Scholar
• BajettaEColleoniMDi BartolomeoMDoxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancerJ Clin Oncol19951310261326197595715
   PubMed Web of Science ®Google Scholar
• Meta-Analysis Group in CancerEfficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancerJ Clin Oncol19981613013089440757
   PubMed Web of Science ®Google Scholar
• MeinsmaRFernandez-SalgueroPVan KuilenburgABVan GennipAHGonzalezFJHuman polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilureaDNA Cell Biol1995141167832988
   PubMed Web of Science ®Google Scholar
• ShirasakaTShimamotoYOhshimoHDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnticancer Drugs1996755485578862723
   PubMed Web of Science ®Google Scholar
• El-SayedYMSadeeWMetabolic activation of ftorafur [R,S-1-(tetrahyro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathwayBiochem Pharmacol19823118300630086814451
   PubMed Web of Science ®Google Scholar
• NakajimaMFukamiTYamanakaHComprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populationsClin Pharmacol Ther200680328229716952495
   PubMed Web of Science ®Google Scholar
• ShimadaTYamazakiHGuengerichFPEthnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P450 2A6 in liver microsomes of Japanese and Caucasian populationsXenobiotica19962643954039173680
   PubMed Web of Science ®Google Scholar
• HiroseTFujitaKNishimuraKPharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancerOncol Rep201024252953620596643
   PubMed Web of Science ®Google Scholar
• HallerDGCassidyJClarkeSJPotential regional differences for the tolerability profiles of fluoropyrimidinesJ Clin Oncol200826132118212318445840
   PubMed Web of Science ®Google Scholar
• SugimachiKMaeharaYHorikoshiNAn early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancersOncology199957320221010545788
   PubMed Web of Science ®Google Scholar
• SakataYOhtsuAHorikoshiNSugimachiKMitachiYTaguchiTLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patientsEur J Cancer19983411171517209893658
   PubMed Web of Science ®Google Scholar
• KoizumiWKuriharaMNakanoSHasegawaKPhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancerOncology200058319119710765119
   PubMed Web of Science ®Google Scholar
• BokuNYamamotoSShiraoKRandomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. (JCOG9912) [abstract]J Clin Oncol200725Suppl 18LBA4513
   Google Scholar
• KoizumiWTanabeSSaigenjiKPhase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancerBr J Cancer200389122207221214676796
   PubMed Web of Science ®Google Scholar
• KoizumiWNaraharaHHaraTS-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialLancet Oncol20089321522118282805
   PubMed Web of Science ®Google Scholar
• NakaharaHIishiHImamuraHRandomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Gastric Cancer2011141728021340666
   PubMed Web of Science ®Google Scholar
• KimYHKoizumiWLeeKHRandomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial [abstract]J Clin Oncol201129Suppl 4721115871
   PubMed Web of Science ®Google Scholar
• Asan Medical CenterTrial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer (SOS)ClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)June 52009 [updated on September 26, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00915382 NLM identifier: NCT00915382
   Google Scholar
• AjaniJAFaustJIkedaKPhase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinomaJ Clin Oncol200523286957696516145066
   PubMed Web of Science ®Google Scholar
• LenzHJLeeFCHallerDGExpanded safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II studyCancer20071091334017133415
   PubMed Web of Science ®Google Scholar
• AjaniJALeeFCSinghDAMulticenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol200624466366716446338
   PubMed Web of Science ®Google Scholar
• AjaniJARodriguezWBodokyGMulticenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trialJ Clin Oncol20102891547155320159816
   PubMed Web of Science ®Google Scholar
• SakuramotoSSasakoMYamaguchiTAdjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidineN Engl J Med2007357181810182017978289
   PubMed Web of Science ®Google Scholar
• BonenkampJJHermansJSasakoMExtended lymph-node dissection for gastric cancerN Engl J Med19993401290891410089184
   PubMed Web of Science ®Google Scholar
• CuschieriAWeedenSFieldingJPatient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-Operative GroupBr J Cancer1999799–101522153010188901
   PubMed Web of Science ®Google Scholar
• SasakoMSanoTYamamotoSD2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancerN Engl J Med2008359545346218669424
   PubMed Web of Science ®Google Scholar
• KangYKKangWKShinDBCapecitabine/cisplatin versus 5-fluorouracil/cisplatin as first line therapy patients with advanced gastric cancer: a randomised phase III noninferiority trialAnn Oncol200920466667319153121
   PubMed Web of Science ®Google Scholar
• CunninghamDStarlingNRaoSCapecitabine and oxaliplatin for advanced esophagogastric cancerN Engl J Med20083581364618172173
   PubMed Web of Science ®Google Scholar
• LeeJLKangYKKangHJA randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancerBr J Cancer200899458459018665164
   PubMed Web of Science ®Google Scholar
• KangYOhtsuAVan CutsemEAVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) [abstract]J Clin Oncol201028Suppl 18LBA4007
   Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• OkinesAFAshleySECunninghamDEpirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-f inding study for the prospective multicenter, randomized, phase II/III REAL-3 trialJ Clin Oncol201028253945395020679619
   PubMed Web of Science ®Google Scholar